Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; A randomized crossover trial

International Journal of Cardiology

Volumn 181, Issue , 2015, Pages 193-199

  Lafeber, M ^a   Grobbee, D E ^a   Schrover, I M ^a   Thom, S ^b   Webster, R ^c   Rodgers, A ^c   Visseren, F L J ^a   Bots, M L ^a   Spiering, W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

Aspirin; Bloodpressure lowering agent; Cardiovascular prevention; Fixed dose combination pill; Polypill; Statin

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS;

EID: 84947201498     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.176     Document Type: Article

References (23)

1. M. Lafeber, W. Spiering, K. Singh, R.K. Guggilla, V. Patel, and R. Webster The cardiovascular polypill in high-risk patients Eur. J. Cardiovasc. Prev. Rehabil. 19 2012 1234 1242
2. K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, and U. Keil Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
3. S. Yusuf, S. Islam, C.K. Chow, S. Rangarajan, G. Dagenais, and R. Diaz Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 2011 1231 1243
4. S. Thom, N. Poulter, J. Field, A. Patel, D. Prabhakaran, and A. Stanton Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial JAMA 310 2013 918 929
5. P.J. Jones, and D.A. Schoeller Evidence for diurnal periodicity in human cholesterol synthesis J. Lipid Res. 31 1990 667 673
6. T.S. Parker, D.J. McNamara, C.D. Brown, R. Kolb, E.H. Ahrens Jr., and A.W. Alberts Plasma mevalonate as a measure of cholesterol synthesis in man J. Clin. Investig. 74 1984 795 804
7. Y. Saito, S. Yoshida, N. Nakaya, Y. Hata, and Y. Goto Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study Arterioscler. Thromb. 11 1991 816 826
8. A. Wallace, D. Chinn, and G. Rubin Taking simvastatin in the morning compared with in the evening: randomised controlled trial BMJ 327 2003 788
9. R.C. Hermida, D.E. Ayala, C. Calvo, and J.E. Lopez Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients J. Am. Coll. Cardiol. 46 2005 975 983
10. J.D. Snoep, M.M. Hovens, S.M. Pasha, M. Frolich, H. Pijl, and J.T. Tamsma Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines Hypertension 54 2009 1136 1142
11. R.C. Hermida, D.E. Ayala, A. Mojon, and J.R. Fernandez Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study Chronobiol. Int. 27 2010 1629 1651
12. B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, and M. Burnier Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories BMJ 336 2008 1114 1117
13. M. Lafeber, D.E. Grobbee, M.L. Bots, S. Thom, R. Webster, and A. Rodgers The Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and design Eur. J. Prev. Cardiol. 21 4 2014 425 433
14. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J. Hypertens. 25 2007 1105 1187
15. K.C. Farmer Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice Clin. Ther. 21 1999 1074 1090 (discussion 3)
16. D.E. Morisky, A. Ang, M. Krousel-Wood, and H.J. Ward Predictive validity of a medication adherence measure in an outpatient setting J. Clin. Hypertens. (Greenwich) 10 2008 348 354
17. M. Gallerani, R. Manfredini, L. Ricci, A. Cocurullo, C. Goldoni, and M. Bigoni Chronobiological aspects of acute cerebrovascular diseases Acta Neurol. Scand. 87 1993 482 487
18. G. Mancia, A. Ferrari, L. Gregorini, G. Parati, G. Pomidossi, and G. Bertinieri Blood pressure and heart rate variabilities in normotensive and hypertensive human beings Circ. Res. 53 1983 96 104
19. M.W.B.C. Millar-Craig, and E.B. Raftery Circadian variation of blood-pressure Lancet 1 1978 795 797
20. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 2001 1296 1310
21. C.I. Coleman, M.S. Roberts, D.M. Sobieraj, S. Lee, T. Alam, and R. Kaur Effect of dosing frequency on chronic cardiovascular disease medication adherence Curr. Med. Res. Opin. 25 2012 669 680
22. L.K. Newby, N.M. LaPointe, A.Y. Chen, J.M. Kramer, B.G. Hammill, and E.R. DeLong Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease Circulation 113 2006 203 212
23. A. Undas, Z. Siudak, K. Brummel-Ziedins, K.G. Mann, and W. Tracz Prothrombinase formation at the site of microvascular injury and aspirin resistance: the effect of simvastatin Thromb. Res. 125 2010 283 285